BRD2 and familial pancreatic carcinoma: In pancreatic cancer, cancer-associated fibroblasts support cancer cell progression and cause chemoresistance; therefore, fibroblast-targeting therapy is evolving as a new candidate for treating pancreatic cancer.[30] It is difficult to distinguish between NAT-related fibrosis and reactive fibrosis because pancreatic cancer is often associated with pancreatitis.[29] When we defined encapsulating fibrosis by the appearance of 2 mm band-like patterns of fibrosis, we could distinguish treatment effects from reactive changes.